Tomer Pontifax (Israel) V, ... Net Worth

The estimated Net Worth of Tomer Pontifax (Israel) V, ... is at least $2.03 Миллион dollars as of 11 November 2019. Tomer V owns over 250,000 units of 89bio Inc stock worth over $2,027,500 and over the last 5 years Tomer sold ETNB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Tomer V ETNB stock SEC Form 4 insiders trading

Tomer has made over 1 trades of the 89bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Tomer bought 250,000 units of ETNB stock worth $4,000,000 on 11 November 2019.

The largest trade Tomer's ever made was buying 250,000 units of 89bio Inc stock on 11 November 2019 worth over $4,000,000. On average, Tomer trades about 250,000 units every 0 days since 2019. As of 11 November 2019 Tomer still owns at least 250,000 units of 89bio Inc stock.

You can see the complete history of Tomer V stock trades at the bottom of the page.

Insiders trading at 89bio Inc

Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... и Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.

What does 89bio Inc do?

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Complete history of Tomer V stock trades at 89bio Inc

89bio Inc executives and stock owners

89bio Inc executives and other stock owners filed with the SEC include:

• Rohan Palekar,
  Chief Executive Officer, Director
• Rohan Palekar,
  CEO & Director
• Hank Mansbach,
  Chief Medical Officer
• Dr. Harry Mansbach M.D.,
  Chief Medical Officer
• Dr. Hank Mansbach M.D.,
  Chief Medical Officer
• Quoc Le-Nguyen,
  Chief Technical Operations Officer and Head of Quality
• Quoc Le-Nguyen,
  Chief Technical Operations Officer & Head of Quality
• Ram Waisbourd,
  Chief Operating Officer and Chief Business Officer
• Michael Hayden,
  Independent Director
• Anat Naschitz,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Derek DiRocco,
  Independent Director
• Ryan Martins,
  Chief Financial Officer
• Steven Altschuler,
  Independent Chairman of the Board of Director
• Yun Bai,
  VP & Head of CMC
• Amanda Hill,
  VP of People & Culture
• Melissa Abel,
  VP of Commercial Strategy & Communication
• Shiva K. Natarajan,
  VP of Fin. & Principal Accounting Officer
• Ram Waisbourd,
  COO & Chief Bus. Officer
• Ryan Stephen Martins,
  Chief Financial Officer
• Charles Mc Wherter,
  
• Tomer Pontifax (Israel) V, ...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Capital Partners Iii, Llc L...,
  
• Kathleen Laporte,
  
• Edward Morrow Iii Atkinson,
  
• Capital Management, L.P.Ra ...,
  
• Harry H Mansbach,
  Chief Medical Officer
• Lota S. Zoth,
  
• Martin Babler,
  
• Francis Willard Sarena,
  Chief Operating Officer